Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Palisade Bio has an average analyst recommendation of "Moderate Buy" from eight brokers (1 sell, 6 buy, 1 strong buy) with an average 12‑month price target of $10.20.
• Shares were down about 7.5% to $1.97, valuing the company near $330M; the stock is unprofitable (P/E -0.93), has a 12‑month range of $0.53–$2.86, and roughly 11.8% is owned by institutions.
• Palisade Bio is a clinical‑stage biotech focused on localized immunotherapies, with lead candidate PDS0108 — an intratumoral TLR9 agonist — currently in Phase 1/2 trials for advanced solid tumors.

Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.20.

Several research analysts recently issued reports on the company. B. Riley Financial assumed coverage on Palisade Bio in a research report on Friday, January 9th. They set a "buy" rating and a $7.00 target price for the company. Wolfe Research assumed coverage on Palisade Bio in a research report on Thursday, April 9th. They set an "outperform" rating and a $7.00 target price for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Palisade Bio in a research report on Thursday, January 22nd. HC Wainwright assumed coverage on Palisade Bio in a research report on Thursday, March 26th. They set a "buy" rating and a $7.00 target price for the company. Finally, Wall Street Zen raised Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Cetera Investment Advisers bought a new position in shares of Palisade Bio in the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio in the 4th quarter worth about $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio in the 4th quarter worth about $28,000. Atom Investors LP bought a new position in shares of Palisade Bio in the 4th quarter worth about $33,000. Finally, Barclays PLC bought a new position in shares of Palisade Bio in the 4th quarter worth about $35,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Stock Down 7.5%

Shares of NASDAQ:PALI opened at $1.97 on Wednesday. The firm has a market cap of $329.83 million, a P/E ratio of -0.93 and a beta of 1.52. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.86. The business has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $1.92.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.